10 terminated. 10 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Terminated 10 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Disease: new trials by email Literature Review of Disease trials Research Report on Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 Budigalimab, Placebo for Budigalimab, ABBV-382 - Human Immuno-deficiency Virus (HIV) Disease | Phase 2 | Terminated | AbbVie | 163 | 2023-10-12 | 2026-11-06 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies 1A46 Injection - Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder) | Phase 1 / Phase 2 | Terminated | Chimagen Biosciences, Ltd | 7 | 2022-08-30 | 2025-02-13 |
| Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream Betamethasone Dipropionate Nasal Cream 0.0644%, Pre-filled syringe and applicator device - Chronic Rhinosinusitis (Diagnosis) | Phase 1 / Phase 2 | Terminated | Oticara Australia PTY LTD | 2 | 2022-02-23 | 2024-05-02 |
| Application of S26E for Diabetic Foot Ulcer Healing Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers, S26E - Diabetic Foot, Neuropathic Foot Ulcer | Phase 2 | Terminated | National and Kapodistrian University of Athens | 5 | 2020-05-15 | 2022-06-08 |
| A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Recurrent Basal Cell Carcinoma | Phase 2 | Terminated | Sol-Gel Technologies, Ltd. | 50 | 2019-12-20 | 2026-07-21 |
| Diagnostic Imaging for Clear Cell Renal Cell Carcinoma Ioflupane I123 - Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | Region Skane | 5 | 2017-07-14 | 2019-06-21 |
| Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease Adrabetadex - Niemann-Pick Disease, Type C | Phase 2 / Phase 3 | Terminated | Mandos LLC | 66 | 2015-12-23 | 2023-08-29 |
| Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma I-124-CLR1404 - Glioblastoma | Phase 2 | Terminated | Cellectar Biosciences, Inc. | 7 | 2014-02-01 | 2015-09-09 |
| A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study quetiapine - Anorexia Nervosa | Phase 2 | Terminated | University of South Florida | 24 | 2007-02-01 | 2012-06-18 |
Anemia, Sickle Cell (1) · Anorexia (1) · Anorexia Nervosa (1) · Basal Cell Nevus Syndrome (1) · Carcinoma, Basal Cell (1) · Carcinoma, Renal Cell (1) · Cognitive Dysfunction (1) · Deglutition Disorders (1) · Diabetic Foot (1) · Glioblastoma (1) · Glioma (1) · Lymphoma, Non-Hodgkin (1) · Mobility Limitation (1) · Niemann-Pick Disease, Type C (1)
Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Hemic and Lymphatic Diseases (3) · Neoplasms, Glandular and Epithelial (3) · Carcinoma (2) · Hematologic Diseases (2) · Lymphatic Diseases (2) · Mental Disorders (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Signs and Symptoms (2)
2-Hydroxypropyl-beta-cyclodextrin (1) · Biosimilar Pharmaceuticals (1) · Cyclodextrins (1) · Cyclophosphamide (1) · Exchange Transfusion, Whole Blood (1) · Mesna (1) · Quetiapine Fumarate (1) · Rituximab (1) · Sirolimus (1) · Standard of Care (1) · Whole-Body Irradiation (1) · budigalimab (1) · ioflupane (1) · siplizumab (1)
AbbVie (1) · Cellectar Biosciences, Inc. (1) · Chimagen Biosciences, Ltd (1) · Columbia University (1) · Mandos LLC (1) · National and Kapodistrian University of Athens (1) · Oticara Australia PTY LTD (1) · Region Skane (1) · Sol-Gel Technologies, Ltd. (1) · University of South Florida (1)
United States (7) · Australia (2) · France (2) · Germany (2) · United Kingdom (2) · Belgium (1) · Brazil (1) · Canada (1) · Greece (1) · Italy (1) · Japan (1) · New Zealand (1) · Poland (1) · Puerto Rico (1) · Singapore (1)
Abass Alavi, MD (1) · Jana Portnow, MD (1) · John Kuo, MD, PhD (1) · Markus Y Mapara, MD, PhD (1) · Peter Elfving, M.D. PhD (1)
2015 (1), 2016 (1), 2023 (1)